Curcuminoid Treatment For Knee Osteoarthritis: A Randomized Double-blind Placebo-controlled Trial
Notes for this study:
||VAS. Figure 3.
|Number of Subjects
||18-29, 30-44, 45-64, 65+
||Obese, Overweight, Average, Underweight
In a randomized, double-blind, placebo-controlled trial, 53 people with knee osteoarthritis were assigned to take 1,500 mg of a curcuminoid complex (95% curcuminoids) with 15 mg of piperine or placebo daily for 6 weeks.
25% of participants didn't complete the study and weren't analyzed. The primary outcome was the change in the Western Ontario And McMaster Universities Osteoarthritis Index (WOMAC), which assessed osteoarthritis symptoms broadly, including pain, function, and stiffness. The curcuminoid group saw a notable, statistically significant reduction in the global WOMAC scale score and pain, and an improvement in function compared with the placebo group, but not for stiffness.
The secondary outcomes were pain on a visual analog scale, and score on the Lequesne’s pain functional index and the curcuminoid group saw notable, statistically significant improvements compared with the placebo group for both.
The participants in the curcuminoid group tended to use fewer NSAIDs over the course of the study.